Threshold Pharmaceuticals, Inc.

Obi Pharma Inc.

Molecular Templates, Inc.

Immunogenesis, Inc.

Jian-Xin Duan

Mark D Matteucci

Hailong Jiao

Yeyu Cao

Xiaohong Cai

Jing Yuan Ma

Nipun Davar

Denise Andersen

Photon Rao

Stewart Kroll

Jacob Kaizerman

Harold E Selick

Charles Praray Hart

Damian Handisides

Donald Jung

Steve Ammons

John G Curd

Jessica D Sun

Charles P Hart

Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Nitrobenzyl derivatives of anti-cancer agents

Provided herein are compounds of formula I, wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds. 

DNA alkylating agents

Provided herein are compounds of formula (I)-(VI): wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

Aziridine containing DNA alkylating agents

The present invention provides a new method for making TH-302 and solid forms thereof. The compound in its solid form is an effective anti-cancer agent and may be used in various pharmaceutical compositions, and are particularly effective for the treatment of cancer. The invention also provides a method for preparing such compounds and forms and for treating cancer in a mammal comprising the step of administering a therapeutically effective amount of a solid form of TH-302 thereof.

TH-302 solid forms and methods related thereto

Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N'-bis(ethylene)phosphoramidate, and methods of treating cancer comprising administering such compounds. 

(R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation

Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds. 

Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.

Phosphoramidate alkylator prodrugs

Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.

Treatment of cancer using hypoxia activated prodrugs

The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment.

Treatment of cancer with glufosfamide in patients not receiving insulin therapy

Various 14-nitro, 14-amino, and 14-substituted amino camptothecin derivatives are useful in the treatment of cancer and other hyperproliferative diseases. 14-Nitro camptothecin derivatives are conveniently prepared by reacting a camptothecin derivative with fuming nitric acid, optionally employing acetic anhydride as a solvent.

Camptothecin derivatives

Compositions containing, and, methods administering, TH302, are useful in treatment of cancer and other hyper-proliferative diseases.

Growing community of inventors

South San Francisco, CA, United States of America

Jian-Xin Duan